HC HCWB HCW Biologics Inc. Loading... : Bullish and Bearish Analyst Opinions

The author alleges HCWB management concealed a signed Akron Biotech exclusive distribution deal for HCW11-006 (with milestone payments and recurring technical fees) in order to first push a dilutive Schedule 14A, deliberately crashing the price to scare retail investors while insiders accumulate at low thresholds. The post further claims key commercial assets HCW11-006 (in vivo) and alopecia drug HCW9302 were transferred to Beijing Trimmune Biotech for a pittance, structurally shielded from US bankruptcy under Section 9.2.2 of Exhibit 10.40, leaving public shareholders to absorb 100% of operating losses against a $108.5M accumulated deficit and going-concern warning. It also alleges an admitted material weakness in internal controls artificially overstated EPS by $0.80 to $2.19, used to justify cheap private placements at $2.585, and that a Special Reserve of 2,500,000 shares (111.7% of outstanding) with insider option tranches at $5/$10/$20/$40 will pass on October 27 because insiders and affiliated hedge funds control over 60% of voting power. Main stated risk is that the October 27 vote is a mathematically predetermined corporate farce, with the author urging shareholders to vote against both proposals and contact securities litigation firms.

Author argues HCW Biologics withheld a positive Akron Biotech distribution agreement to push a dilutive Schedule 14A proxy, crushing the price while insiders accumulate at low strikes. Core commercial assets HCW11-006 and HCW9302 were allegedly transferred to Beijing Trimmune for pennies, sheltered from US liquidation under Exhibit 10.40 Section 9.2.2, leaving public holders with the going-concern liabilities. A material weakness 8-K allegedly overstated EPS by $0.80-$2.19, and Proposal Two seeks a 2.5M-share insider option reserve that a >60% insider voting bloc will pass at the October 27 vote. Main risk is that the author's fraud allegations are unproven and the vote outcome is already priced in.